TransCode Therapeutics is a biopharmaceutical company focused primarily on developing and commercializing drugs and diagnostics for treating and identifying metastatic disease. Co.'s primary therapeutic candidate, TTX-MC138, targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Co.'s other preclinical programs include two solid tumor programs: TTX-siPDL1, a small interfering RNA (siRNA)-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. We show 12 historical shares outstanding datapoints in our RNAZ shares outstanding history coverage, used to compute RNAZ market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing RNAZ market cap history over the course of time is important for investors
interested in comparing RNAZ's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of RNAZ versus a peer is one thing; comparing
RNAZ market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like RNAZ can fluctuate over the course of history.
With this page we aim to empower investors researching RNAZ by allowing them to research the RNAZ market cap history. |
Free RNAZ Email Alerts:
Video: The Importance of Market Cap
